IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
IMUNON (Nasdaq: IMNN) announced oral presentations of PlaCCine® DNA vaccine proof-of-concept data and IMNN-101 clinical results at two vaccine conferences: Oct 23, 2025 (International Vaccines Congress, Orlando) and Nov 6, 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN reported positive six-month Phase 1 data showing better durability versus mRNA after a single dose targeting SARS-CoV-2 Omicron XBB1.5, with up to a 3-fold median increase in serum neutralizing antibody titers at six months and stronger responses in the 2.0 mg and 1.0 mg cohorts. IMNN-101 was safe and well tolerated with no serious adverse effects. The company is seeking strategic partners to advance PlaCCine commercialization, highlighting durability, temperature stability, and scalable manufacturing.
IMUNON (Nasdaq: IMNN) ha annunciato presentazioni orali di dati dimostrativi della vaccino DNA PlaCCine® e risultati clinici IMNN-101 a due conferenze sulle vaccinazioni: 23 ottobre 2025 (International Vaccines Congress, Orlando) e 6 novembre 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN ha riportato dati positivi di fase 1 a sei mesi che mostrano una maggiore durata rispetto all'mRNA dopo una singola dose mirata a SARS-CoV-2 Omicron XBB1.5, con fino a un aumento mediano fino a 3 volte nei titoli neutralizzanti sierici a sei mesi e risposte più forti nei gruppi da 2.0 mg e 1.0 mg. IMNN-101 è stato sicuro e ben tollerato con nessun effetto avverso grave. L'azienda sta cercando partner strategici per avanzare la commercializzazione di PlaCCine, sottolineando durabilità, stabilità a temperatura e produzione scalabile.
IMUNON (Nasdaq: IMNN) anunció presentaciones orales de datos de prueba de concepto de la vacuna de ADN PlaCCine® y de resultados clínicos de IMNN-101 en dos congresos de vacunas: 23 de octubre de 2025 (Congreso Internacional de Vacunas, Orlando) y 6 de noviembre de 2025 (Conferencia Internacional sobre Investigación y Desarrollo de Vacunas, Boston).
IMNN informó datos positivos de fase 1 a seis meses que muestran una mejor durabilidad frente a lRNA tras una dosis única dirigida a SARS-CoV-2 Omicron XBB1.5, con hasta un aumento medio de 3 veces en los títulos neutralizantes séricos a los seis meses y respuestas más fuertes en las cohortes de 2.0 mg y 1.0 mg. IMNN-101 fue seguro y bien tolerado con ningún efecto adverso grave. La empresa busca socios estratégicos para avanzar en la comercialización de PlaCCine, destacando durabilidad, estabilidad a la temperatura y fabricación escalable.
IMUNON (나스닥: IMNN)은 두 개의 백신 학회에서 PlaCCine® DNA 백신의 개념 증명 데이터와 IMNN-101 임상 결과를 구두 발표했다고 발표했습니다: 2025년 10월 23일 (국제 백신 학회, 올랜도) 및 2025년 11월 6일 (백신 연구개발 국제회의, 보스턴).
IMNN은 SARS-CoV-2 오미크론 XBB1.5를 표적으로 한 단일 용량 후 6개월의 1상 데이터를 발표했으며, mRNA 대비 더 나은 지속성을 보였고 6개월에 혈청 중화 항체가가 중간값 최대 3배 증가를 보였으며 2.0 mg 및 1.0 mg 코호트에서 더 강한 반응을 보였습니다. IMNN-101은 안전했고 심각한 이상 반응이 없었다고 보고되었습니다. 회사는 PlaCCine 상용화를 추진하기 위해 전략적 파트너를 찾고 있으며, 지속성, 온도 안정성, 확장 가능한 제조를 강조합니다.
IMUNON (Nasdaq: IMNN) a annoncé des présentations orales des données de concept de preuve du vaccin PlaCCine® ADN et des résultats cliniques d'IMNN-101 lors de deux conférences sur les vaccins: 23 octobre 2025 (Congrès international sur les vaccins, Orlando) et 6 novembre 2025 (Conférence internationale sur la recherche et le développement des vaccins, Boston).
IMNN a rapporté des données positives de phase 1 à six mois montrant une meilleure durabilité par rapport à l'ARNm après une dose unique ciblant SARS-CoV-2 Omicron XBB1.5, avec jusqu'à une augmentation médiane jusqu'à 3 fois des titres d'anticorps neutralisants sériques à six mois et des réponses plus fortes dans les cohortes 2,0 mg et 1,0 mg. IMNN-101 était sûr et bien toléré avec aucun effet indésirable grave. L'entreprise recherche des partenaires stratégiques pour faire progresser la commercialisation de PlaCCine, en mettant en avant la durabilité, la stabilité à la température et la fabrication évolutive.
IMUNON (Nasdaq: IMNN) hat mündliche Präsentationen von PlaCCine® DNA-Impfstoff-Demonstrationsdaten und IMNN-101-Klinikergebnissen auf zwei Impfstoffkonferenzen angekündigt: 23. Oktober 2025 (International Vaccines Congress, Orlando) und 6. November 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN berichtete positive sechsmonatige Phase-1-Daten, die eine bessere Haltbarkeit gegenüber mRNA nach einer einzelnen Dosis zeigen, die SARS-CoV-2 Omicron XBB1.5 gezielt. Bei sechs Monaten gab es eine median 3-fache Erhöhung der Serumneutralisationsantikörpertiter und stärkere Reaktionen in den 2,0 mg- und 1,0 mg-Kohorten. IMNN-101 war sicher und gut verträglich mit keinen schweren Nebenwirkungen. Das Unternehmen sucht strategische Partner, um die PlaCCine-Kommerzialisierung voranzutreiben und hebt Haltbarkeit, Temperaturstabilität und skalierbare Herstellung hervor.
IMUNON (نازداك: IMNN) أعلن عن عروض شفوية لبيانات إثبات المفهوم للقاح PlaCCine® DNA ونتائج IMNN-101 السريرية في مؤتمرين للقاحات: 23 أكتوبر 2025 (المؤتمر الدولي للقاحات، أورلاندو) و6 نوفمبر 2025 (المؤتمر الدولي لأبحاث وتطوير اللقاحات، بوسطن).
أفاد IMNN ببيانات إيجابية للمرحلة الأولى لمدة ستة أشهر تُظهر ثباتاً أفضل مقارنةً بـ mRNA بعد جرعة واحدة تستهدف SARS-CoV-2 Omicron XBB1.5، مع حتى زيادة وسيطة حتى 3 أضعاف في عيارات الأجسام المضادة المحايدة في المصل عند ستة أشهر واستجابات أقوى في مجموعات الجرعة 2.0 mg و1.0 mg. كان IMNN-101 آمناً ومحتمل التحمل بدون آثار جانبية خطيرة. تسعى الشركة إلى شركاء استراتيجيين لتعزيز تسويق PlaCCine، مع التركيز على المتانة، والاستقرار عند درجات الحرارة، والتصنيع القابل للتوسع.
IMUNON (纳斯达克代码：IMNN)宣布在两场疫苗会议上口头披露 PlaCCine® DNA 疫苗概念验证数据及 IMNN-101 临床结果：2025年10月23日（国际疫苗大会，奥兰多）和 2025年11月6日（国际疫苗研究与开发大会，波士顿）。
IMNN 报告了六个月的第一阶段积极数据，显示在针对 SARS-CoV-2 Omicron XBB1.5 的单剂后，相较于 mRNA 的耐久性更好，六个月时血清中和抗体滴度的中位数提升至 最高 3 倍，在 2.0 mg 和 1.0 mg 组显示出更强的反应。IMNN-101 安全且耐受性良好，没有严重不良反应。公司正在寻求战略伙伴，以推动 PlaCCine 的商业化，强调耐久性、对温度的稳定性和可扩展的生产能力。
- Phase 1 six-month durability superior to mRNA after single dose
- NAb titers up to 3-fold median increase at six months
- Higher immune response in 2.0 mg and 1.0 mg cohorts
- No serious adverse effects reported in Phase 1
- Platform advantages: temperature stability and scalable manufacturing
- Phase 1 only; no larger randomized or pivotal trial data reported
- Commercial progress depends on securing strategic partners/non-dilutive funding
Company seeks strategic partners to advance novel PlaCCine technology
LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potential as a next-generation vaccine, today announced that members of its leadership team will deliver oral presentations highlighting IMNN-101, its investigational DNA plasmid vaccine based on the Company’s proprietary PlaCCine® technology platform, including proof-of-concept clinical trial results at the following upcoming vaccine conferences:
5th Edition of International Vaccines Congress (IVC)
Keynote Oral Presentation Title: A promising novel approach to DNA vaccines
Presenting Author: Khursheed Anwer, Ph.D., M.B.A., Executive Vice President and Chief Science Officer, IMUNON, and IVC Scientific Committee Member
Date and Time: Thursday, October 23, 2025, 10:20 a.m. ET
Location: Orlando, Florida
10th International Conference on Vaccine Research and Development
Oral Presentation Title: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines
Presenting Author: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON
Date and Time: Thursday, November 6, 2025, 1:50 p.m. ET
Location: Boston, Massachusetts
In May 2025, IMUNON announced positive six-month data from the Phase 1 trial of IMNN-101 showing proof of concept of the PlaCCine technology, demonstrating better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant. Results also showed IMNN-101 induced up to a 3-fold median increase in the serum neutralizing antibody (NAb) titers from baseline at six months, with initial evidence of a stronger immune response in the two higher dose cohorts (2.0 mg and 1.0 mg) compared to the lower dose cohort (0.5 mg). IMNN-101 was shown to be safe and well tolerated, with no serious adverse effects reported.
To accelerate the development and commercialization of the PlaCCine platform, IMUNON is actively seeking strategic partnerships with leading pharmaceutical and biotechnology companies. These collaborations aim to leverage PlaCCine’s unique advantages—enhanced durability, temperature stability, and scalable manufacturing—to address unmet needs in vaccines for infectious diseases and cancer, while securing non-dilutive funding to advance IMUNON’s broader oncology focused pipeline.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
When will IMUNON (IMNN) present PlaCCine clinical data at the International Vaccines Congress?
What Phase 1 IMNN-101 results did IMUNON (IMNN) report in May 2025?
Which IMNN-101 dose cohorts showed stronger immune responses in the Phase 1 data?
Were there safety concerns reported for IMNN-101 in the Phase 1 trial?
How does IMUNON plan to advance PlaCCine after the Phase 1 results?
What practical advantages does PlaCCine claim for vaccines and manufacturing?
